Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.84 Analyst target: $1.52 Upside: -17.39%
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. The company is headquartered in Camberwell, Australia.
See the full interactive analysis & chart →Informational only — not investment advice.